Epilogue: New Drugs for Neglected Diseases
In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion (year 2000 U.S. dollars) per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real (inflation-adjusted) rate o...
Authors: | ; |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
Cambridge Univ. Press
2011
|
In: |
Cambridge quarterly of healthcare ethics
Year: 2011, Volume: 20, Issue: 2, Pages: 329-334 |
Online Access: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
LEADER | 00000caa a22000002 4500 | ||
---|---|---|---|
001 | 1827985097 | ||
003 | DE-627 | ||
005 | 20230426094854.0 | ||
007 | cr uuu---uuuuu | ||
008 | 221220s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1017/S0963180110000988 |2 doi | |
035 | |a (DE-627)1827985097 | ||
035 | |a (DE-599)KXP1827985097 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
084 | |a 1 |2 ssgn | ||
100 | 1 | |a Pogge, Thomas |e VerfasserIn |4 aut | |
245 | 1 | 0 | |a Epilogue: New Drugs for Neglected Diseases |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion (year 2000 U.S. dollars) per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real (inflation-adjusted) rate of 7.4% annually. According to these estimates, the innovation cost per new medicine today is about $2.1 billion (year 2000 U.S. dollars) or $2.65 billion (year 2010 U.S. dollars). | ||
700 | 1 | |a Hollis, Aidan |e VerfasserIn |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cambridge quarterly of healthcare ethics |d Cambridge : Cambridge Univ. Press, 1992 |g 20(2011), 2, Seite 329-334 |h Online-Ressource |w (DE-627)306655039 |w (DE-600)1499985-7 |w (DE-576)081985010 |x 1469-2147 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2011 |g number:2 |g pages:329-334 |
856 | 4 | 0 | |u https://doi.org/10.1017/S0963180110000988 |x Resolving-System |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/epilogue-new-drugs-for-neglected-diseases/19504A82A0B95C7F822D212384B43464 |x Verlag |z lizenzpflichtig |3 Volltext |
935 | |a mteo | ||
936 | u | w | |d 20 |j 2011 |e 2 |h 329-334 |
951 | |a AR | ||
ELC | |a 1 | ||
ITA | |a 1 |t 1 | ||
LOK | |0 000 xxxxxcx a22 zn 4500 | ||
LOK | |0 001 4235390007 | ||
LOK | |0 003 DE-627 | ||
LOK | |0 004 1827985097 | ||
LOK | |0 005 20221220052659 | ||
LOK | |0 008 221220||||||||||||||||ger||||||| | ||
LOK | |0 035 |a (DE-Tue135)IxTheo#2022-12-06#BACF3C4F0F50622F6B6623730244B4FCFD90B5FB | ||
LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
LOK | |0 092 |o n | ||
LOK | |0 852 |a DE-Tue135 | ||
LOK | |0 852 1 |9 00 | ||
LOK | |0 935 |a ixzs |a ixrk |a zota | ||
ORI | |a SA-MARC-ixtheoa001.raw |